retatrutide triple agonist glp-1 gip glucagon receptors Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide mechanism triple agonist glp-1

TRIUMPH-1 enrolled 2,339 participants with obesity, randomised across four arms: retatrutide 4 mg, 9 mg, 12 mg, or placebo

In contrast to conventional administration methods, such as injections and oral medications, MP offers a non-invasive, effortless, and safe usage for patients of all ages (Jeong et al., 2021)

However, the appetite suppression at higher doses can make it challenging to consume adequate calories to support intense training

They skew older than the average American with a median age of 52, but the patients sampled ranged in age from 26 to 75

et al., Glucagon-like peptide-1, glucose homeostasis and diabetes